Lab
Unilab Corporation
Unilab Corporation was paid $11K by Medicaid between Jun 2019 and Aug 2024, across 109 billing codes. Its largest line is 88175, Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer — 62% of everything it billed.
33Billing provider infoUNILAB CORPORATION
SACRAMENTO, CA 95834
SACRAMENTO, CA 95834
33aNPI1053785345assigned 11/24/2015
33bProvider typeClinical Medical Laboratory
28Total paid$11K
24GClaims32,277
24DCodes billed109
24AFirst – last monthJun 2019 – Aug 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#430 of 561
Median peer was paid$222K
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 28 | $658.00 | |
| 2020 | 586 | $6K | |
| 2021 | 3,246 | $863.16 | |
| 2022 | 4,723 | $878.81 | |
| 2023 | 12,332 | $2K | |
| 2024incomplete | 11,362 | $708.14 |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 62% | 640 | 640 | $7K |
| 88112 | 16% | 329 | 187 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.4% | 1,105 | 1,096 | $957.59 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.3% | 1,111 | 1,102 | $954.38 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.6% | 103 | 102 | $300.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.1% | 286 | 286 | $123.60 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.1% | 387 | 386 | $122.16 |
| 88141 | <1% | 162 | 119 | $32.88 | |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 2,144 | 2,143 | $0.00 |
| 82950 | 0% | 28 | 28 | $0.00 | |
| 86800 | 0% | 13 | 13 | $0.00 | |
| 87340 | 0% | 261 | 261 | $0.00 |
97 more codes
| 86592 | 0% | 600 | $0.00 | |
| 82043 | 0% | 360 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 182 | $0.00 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 0% | 1,454 | $0.00 |
| 85027 | 0% | 417 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 4,990 | $0.00 |
| 85018 | 0% | 193 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 903 | $0.00 |
| 80053 | Comprehensive metabolic panel | 0% | 1,776 | $0.00 |
| 86706 | 0% | 164 | $0.00 | |
| 86140 | 0% | 147 | $0.00 | |
| 82746 | 0% | 242 | $0.00 | |
| 83550 | 0% | 296 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 565 | $0.00 |
| 80048 | Basic metabolic panel (calcium, ionized) | 0% | 150 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 1,025 | $0.00 |
| 86803 | 0% | 573 | $0.00 | |
| 80081 | 0% | 87 | $0.00 | |
| 80050 | General health panel | 0% | 1,088 | $0.00 |
| 82728 | 0% | 367 | $0.00 | |
| 86704 | 0% | 155 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 12 | $0.00 |
| 83735 | 0% | 48 | $0.00 | |
| 84436 | 0% | 51 | $0.00 | |
| 87077 | 0% | 64 | $0.00 | |
| 87088 | 0% | 371 | $0.00 | |
| 84153 | 0% | 94 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 470 | $0.00 |
| 81001 | 0% | 959 | $0.00 | |
| 82607 | 0% | 371 | $0.00 | |
| 87081 | 0% | 106 | $0.00 | |
| 84479 | 0% | 45 | $0.00 | |
| 83014 | 0% | 20 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 95 | $0.00 |
| 87536 | 0% | 13 | $0.00 | |
| 83001 | 0% | 35 | $0.00 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 0% | 248 | $0.00 |
| 85652 | 0% | 203 | $0.00 | |
| 85730 | 0% | 32 | $0.00 | |
| 84402 | 0% | 19 | $0.00 | |
| 87070 | 0% | 19 | $0.00 | |
| 82670 | 0% | 22 | $0.00 | |
| 86376 | 0% | 19 | $0.00 | |
| 86317 | 0% | 16 | $0.00 | |
| 87522 | Neg quan hep c or qual rna | 0% | 30 | $0.00 |
| 83002 | 0% | 16 | $0.00 | |
| 86762 | 0% | 17 | $0.00 | |
| 87147 | 0% | 25 | $0.00 | |
| 84460 | 0% | 39 | $0.00 | |
| 86480 | 0% | 283 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 534 | $0.00 |
| 82570 | 0% | 399 | $0.00 | |
| 84439 | 0% | 428 | $0.00 | |
| 81513 | 0% | 256 | $0.00 | |
| 81243 | 0% | 46 | $0.00 | |
| 83525 | 0% | 58 | $0.00 | |
| 80074 | 0% | 85 | $0.00 | |
| 80076 | 0% | 71 | $0.00 | |
| 82274 | 0% | 206 | $0.00 | |
| 82652 | 0% | 58 | $0.00 | |
| 87338 | 0% | 14 | $0.00 | |
| 83540 | 0% | 318 | $0.00 | |
| 84550 | 0% | 94 | $0.00 | |
| 99199 | Unlisted special service, procedure or report | 0% | 20 | $0.00 |
| 84403 | 0% | 69 | $0.00 | |
| 84466 | 0% | 27 | $0.00 | |
| 83013 | 0% | 69 | $0.00 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 29 | $0.00 |
| 86708 | 0% | 76 | $0.00 | |
| 85610 | 0% | 118 | $0.00 | |
| 86038 | 0% | 76 | $0.00 | |
| 80061 | Lipid panel | 0% | 2,287 | $0.00 |
| 81329 | 0% | 45 | $0.00 | |
| 83655 | 0% | 198 | $0.00 | |
| 87186 | 0% | 82 | $0.00 | |
| 85014 | 0% | 17 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 48 | $0.00 |
| 83020 | 0% | 89 | $0.00 | |
| 87177 | 0% | 14 | $0.00 | |
| 81003 | 0% | 79 | $0.00 | |
| 84450 | 0% | 12 | $0.00 | |
| 86003 | 0% | 45 | $0.00 | |
| 99001 | 0% | 18 | $0.00 | |
| 86200 | 0% | 16 | $0.00 | |
| 82947 | 0% | 12 | $0.00 | |
| 84146 | 0% | 19 | $0.00 | |
| 84702 | 0% | 30 | $0.00 | |
| 84481 | 0% | 12 | $0.00 | |
| 87209 | 0% | 14 | $0.00 | |
| 82248 | 0% | 28 | $0.00 | |
| 85041 | 0% | 15 | $0.00 | |
| 86787 | 0% | 21 | $0.00 | |
| 86735 | 0% | 17 | $0.00 | |
| 82785 | 0% | 13 | $0.00 | |
| 85007 | 0% | 12 | $0.00 | |
| 86765 | 0% | 16 | $0.00 | |
| 86431 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.